ABSTRACT
OBJECTIVE: The mismatch repair (MMR) genes play a central role for the onset of cancer. One of these genes is hMSH2. A differential hMSH2 protein expression has been detected in the mononuclear fraction of peripheral blood of patients with breast cancer when compared to healthy women. This work aims to evaluate the expression of hMSH2 in patients diagnosed with breast cancer undergoing treatment at various stages of the disease to verify its potential use as a prognostic marker. PATIENTS AND METHODS: Immunohistochemical expression of hMSH2 at different stages of breast cancer in 40 patients biopsy samples were analyzed. RESULTS: hMSH2 has a considerable increased expression in all groups of patients with tumors, when compared to patients without tumors. CONCLUSIONS: immunohistochemistry indeed can be a great tool for the diagnosis of breast cancer, as it is an easy and versatile technique.
Subject(s)
Breast Neoplasms/genetics , Genomic Instability/genetics , Lymph Nodes/metabolism , MutS Homolog 2 Protein/metabolism , Nuclear Proteins/genetics , Adaptor Proteins, Signal Transducing/genetics , Adult , Breast Neoplasms/pathology , DNA Mismatch Repair , Female , Humans , Immunohistochemistry , Middle AgedABSTRACT
OBJECTIVE: The acute lymphocytic leukemia is a hematopoietic cancer that occurs predominantly in children. Methotrexate is one of the most useful drugs in cancer chemotherapy. The aim of the study was to develop and validate the methodology of high performance liquid chromatography (HPLC) with ultraviolet detection for methotrexate dosage and to determine its concentration in plasma samples from children with leukemia. PATIENTS AND METHODS: The study included patients from the outpatient care of pediatric oncology at the Faculty of Medicine of ABC carriers in treatment of leukemia. The study was conducted in chromatographic model Agilent 1100 with UV detector at 302 nm and by the method of ELISA microplate reader capable of reading absorbance at 450 nm. RESULTS: We obtained satisfactory results of selectivity, accuracy, linearity, limit of quantification (LOQ), limit of detection (LOD), precision and robustness and apply the basic criteria for validation as RE No. 899, of May 29, 2003 Guide validation of analytical and bioanalytical National Agency Health Surveillance (ANVISA). CONCLUSIONS: We conclude that results for linearity/concentration range, precision, robustness, limit of quantification and detection limits are within the acceptance criteria defined by ANVISA and that the developed analytical method is valid and feasible to be used as a tool in monitoring therapy of methotrexate.
